Advertisement
GOSS vs XNCR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GOSS is a Hold and XNCR is a StrongBuy.
GOSS's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for GOSS turned positive on October 12, 2026. Looking at past instances where GOSS's MACD turned positive, the stock continued to rise in 34 of 38 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on GOSS as a result. In 64 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
Following a +15.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where GOSS advanced for three days, in 214 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 48 cases where GOSS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GOSS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
GOSS broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GOSS entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.636) is normal, around the industry mean (3.498). P/E Ratio (-0.230) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.666) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. GOSS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GOSS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
XNCR in upward trend: 10-day moving average crossed above 50-day moving average on October 28, 2026
The 10-day moving average for XNCR crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on XNCR as a result. In 51 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for XNCR just turned positive on October 21, 2026. Looking at past instances where XNCR's MACD turned positive, the stock continued to rise in 32 of 47 cases over the following month. The odds of a continued upward trend are 68%.
XNCR moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +10.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where XNCR advanced for three days, in 189 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XNCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
XNCR broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XNCR entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.282) is normal, around the industry mean (3.498). P/E Ratio (-16.551) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.740) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (16.949) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. XNCR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XNCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
GOSS | XNCR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 21 | 45 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 33 Fair valued | 16 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 98 | |
SMR RATING 1..100 | 100 | 97 | |
PRICE GROWTH RATING 1..100 | 65 | 34 | |
P/E GROWTH RATING 1..100 | 28 | 97 | |
SEASONALITY SCORE 1..100 | 48 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XNCR's Valuation (16) in the Biotechnology industry is in the same range as GOSS (33) in the Pharmaceuticals Major industry. This means that XNCR’s stock grew similarly to GOSS’s over the last 12 months.
XNCR's Profit vs Risk Rating (98) in the Biotechnology industry is in the same range as GOSS (100) in the Pharmaceuticals Major industry. This means that XNCR’s stock grew similarly to GOSS’s over the last 12 months.
XNCR's SMR Rating (97) in the Biotechnology industry is in the same range as GOSS (100) in the Pharmaceuticals Major industry. This means that XNCR’s stock grew similarly to GOSS’s over the last 12 months.
XNCR's Price Growth Rating (34) in the Biotechnology industry is in the same range as GOSS (65) in the Pharmaceuticals Major industry. This means that XNCR’s stock grew similarly to GOSS’s over the last 12 months.
GOSS's P/E Growth Rating (28) in the Pharmaceuticals Major industry is significantly better than the same rating for XNCR (97) in the Biotechnology industry. This means that GOSS’s stock grew significantly faster than XNCR’s over the last 12 months.
| GOSS | XNCR | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 79% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| Momentum ODDS (%) | 2 days ago 81% | 2 days ago 68% |
| MACD ODDS (%) | 2 days ago 89% | 2 days ago 68% |
| TrendWeek ODDS (%) | 2 days ago 85% | 2 days ago 78% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 73% |
| Advances ODDS (%) | 2 days ago 85% | 2 days ago 75% |
| Declines ODDS (%) | 9 days ago 89% | 29 days ago 82% |
| BollingerBands ODDS (%) | 2 days ago 86% | 2 days ago 60% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GOSS’s FA Score shows that 2 FA rating(s) are green while XNCR’s FA Score has 1 green FA rating(s).
- GOSS’s FA Score: 2 green, 3 red.
- XNCR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GOSS’s TA Score shows that 3 TA indicator(s) are bullish while XNCR’s TA Score has 5 bullish TA indicator(s).
- GOSS’s TA Score: 3 bullish, 4 bearish.
- XNCR’s TA Score: 5 bullish, 5 bearish.
Price Growth
GOSS (@Biotechnology) experienced а +21.55% price change this week, while XNCR (@Biotechnology) price change was +28.56% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
GOSS is expected to report earnings on Nov 11, 2026.
XNCR is expected to report earnings on Feb 24, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
GOSS and
Correlation & Price change
A.I.dvisor indicates that over the last year, GOSS has been loosely correlated with LITS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GOSS jumps, then LITS could also see price increases.
| Ticker / NAME | Correlation To GOSS | 1D Price Change % | ||
|---|---|---|---|---|
| GOSS | 100% | +5.97% | ||
| LITS - GOSS | 46% Loosely correlated | +0.86% | ||
| APVO - GOSS | 41% Loosely correlated | -4.42% | ||
| IDYA - GOSS | 38% Loosely correlated | -0.87% | ||
| XNCR - GOSS | 38% Loosely correlated | +2.07% | ||
| SYRE - GOSS | 38% Loosely correlated | -4.15% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| USXF | 63.38 | -0.30 | -0.47% |
| iShares ESG Advanced MSCI USA ETF (USXF) | |||
| GLIN | 47.21 | -0.25 | -0.53% |
| VanEck India Growth Leaders ETF (GLIN) | |||
| CDX | 19.83 | -0.25 | -1.25% |
| Simplify High Yield ETF (CDX) | |||
| BABW | 17.25 | -0.50 | -2.84% |
| Roundhill BABA WeeklyPay ETF (BABW) | |||
| BAVA | 22.60 | -0.81 | -3.45% |
| Bitwise Avalanche ETF (BAVA) | |||